V. Israel

发表

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

J. Crowley, K. Kelly, P. Bunn, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen‐associated venous thrombosis and activated protein C resistance due to factor V leiden

V. Israel, H. Liebman, I. Weitz, 1997, Cancer.

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

V. Israel, S. Tagawa, D. Raghavan, 2004, Investigational New Drugs.

Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.

J. Doroshow, V. Israel, D. Gandara, 2004, Clinical lung cancer.

Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial

E. Perez, J. Doroshow, V. Israel, 2001, Cancer Chemotherapy and Pharmacology.

Intraperitoneal 5-fluoro-2′-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study

A. Tulpule, V. Israel, Kenneth K. Chan, 2004, Cancer Chemotherapy and Pharmacology.

Chemotherapy-Induced Activation of Hemostasis: Effect of a Low Molecular Weight Heparin (Dalteparin Sodium) on Plasma Markers of Hemostatic Activation

C. Presant, V. Israel, J. Waisman, 2002, Thrombosis and Haemostasis.

A California Cancer Consortium phase II trial of concurrent twice-weekly paclitaxel, weekly carboplatin and radiation followed by paclitaxel/carboplatin consolidation for stage III non-small-cell lung cancer

J. Doroshow, V. Israel, D. Gandara, 2000 .

Phase II Study of Gemcitabine and Cisplatin in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group Study 9718

J. Crowley, K. Kelly, V. Israel, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma

M. Socinski, V. Israel, A. Sandler, 2002, Cancer.

Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial.

M. Socinski, V. Israel, A. Sandler, 2001, Clinical lung cancer.

Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.

M. Socinski, V. Israel, A. Sandler, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.

J. Doroshow, V. Israel, D. Gandara, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer.

V. Israel, D. Gandara, M. Edelman, 2003, Lung cancer.